Skip to main content
  • Share to Twitter
  • Share to Linked In
  • Share to Facebook
  • Share to Google Plus

© Janssen Products, LP 2015. All rights reserved. The use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy. This site is published by Janssen Products, LP which is solely responsible for its contents. This site is intended for use by healthcare professionals in the United States and its territories. Janssen Products, LP recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States.

  • Share to Twitter
  • Share to Linked In
  • Share to Facebook
  • Share to Google Plus

Efficacy

YONDELIS® was studied in patients with unresectable or metastatic liposarcoma and leiomyosarcoma who had been treated with a prior anthracycline-containing regimen.

SAFETY

YONDELIS® has an established safety profile.

DOSING AND ADMINISTRATION

MECHANISM OF ACTION

YONDELIS® mechanism of action.

SUPPORT

Janssen CarePath is a comprehensive support program to help your patients start and stay on therapy and assist you and your office staff with access and affordability questions. The YONDELIS® Education Support (Y.E.S.) program provides patients with access to oncology nurses when they have questions about their disease or YONDELIS®.

ORDERING

Information regarding specialty distributors authorized to sell YONDELIS®.

FOR PATIENTS

Information for patients and caregivers about what to expect during treatment with YONDELIS®.

  • Share to Twitter
  • Share to Linked In
  • Share to Facebook
  • Share to Google Plus

© Janssen Products, LP 2015. All rights reserved. The use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy. This site is published by Janssen Products, LP which is solely responsible for its contents. This site is intended for use by healthcare professionals in the United States and its territories. Janssen Products, LP recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States.

INDICATION

YONDELIS® (trabectedin) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.

 

Important Safety Information

 

Indication

INDICATION

YONDELIS® (trabectedin) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.

Error Message Icon

Please hold your device
in the portrait position.